Table IV.
Multivariate analysis.
| Risk factor for SLN metastasis | P-value | Relative risk | 95% CI |
|---|---|---|---|
| Age | 0.0938 | 1.00 | 0.93–1.07 |
| Maximum tumor size | 0.1477 | 2.09 | 0.81–8.24 |
| ly | |||
| ly0 | 0.0138a | 1.00 | 1.95–5.14×1019 |
| ly1–3 | 7.08×108 | ||
| v | |||
| v0 | 0.4950 | 1.00 | 0.27–20.47 |
| v1 | 2.03 | ||
| NG | |||
| 1 | 0.1258 | 1.00 | 0.68–29.32 |
| 2–3 | 4.05 | ||
| ER status | |||
| Negative | 0.8965 | 1.00 | 0.105–12.33 |
| Positive | 1.16 | ||
| PgR status | |||
| Negative | 0.0823 | 1.00 | 0.791–145.56 |
| Positive | 7.30 | ||
| HER2 status | |||
| Negative | 0.2760 | 1.00 | 0.43–25.07 |
| Positive | 3.00 | ||
a
P<0.05.
SLN, sentinel lymph node; CI, confidence interval; ly, lymph vessel invasion; v, vessel invasion; NG, nuclear grade; ER, estrogen receptor; PgR, progesteron receptor; HER2, human epidermal growth factor type 2.